Case study · Site-specific FDA 510(k) · NGS

FDA clearance for an at-home celiac genetic risk test

Working with Targeted Genomics, ResearchDx designed the GlutenID assay, wrote every protocol, ran all analytical validation and analyzed the data. The project went from start to FDA submission in 18 months, and the test is now cleared for use in our CLIA-certified laboratory, PacificDx.

At a glance

The project in brief

Client

Targeted Genomics, LLC

Test

GlutenID Celiac Genetic Health Risk Test

FDA outcome

Site-specific 510(k) clearance, K241456 (announced January 28, 2025)

Project start to submission

18 months

Device class

Class II, Genetic Health Risk Assessment System (21 CFR 866.5950)

Use

Over-the-counter, direct-to-consumer, adults 18+

Sample

Saliva, collected at home

Technology

Custom NGS-based SNP panel on the Illumina MiSeqDx, with a full bioinformatics pipeline for haplotype reporting

Testing site

PacificDx, a ResearchDx company: the only laboratory covered by the clearance

The challenge

A consumer genetic test with a higher bar

Targeted Genomics wanted to sell a celiac disease genetic risk test straight to consumers, with no prescription. For an over-the-counter genetic test, FDA requires Class II special controls: full analytical validation, plus proof that lay users understand their results.

The test also went further than the cleared comparison device. The predicate, 23andMe's Personal Genome Service celiac test (DEN160026), reports one risk haplotype, HLA-DQ2.5, using a microarray. GlutenID reports four (HLA-DQ2.5, DQ8, DQ7 and DQ2.2) from six genetic variants, using next-generation sequencing.

The submission was site-specific: FDA reviews the assay as performed in one named laboratory, so that lab's equipment, staff and procedures are part of what gets cleared.

Our approach

From assay design to a cleared test

Working with Targeted Genomics, ResearchDx designed the assay, wrote every protocol, performed all of the analytical validation studies and did all of the data analysis, then secured the clearance on Targeted Genomics' behalf.

1

Pathway and predicate

A 510(k) under 21 CFR 866.5950, product code PTA, with 23andMe's celiac genetic health risk test as the predicate.

2

Assay design

Saliva collected in an FDA-cleared ORAcollect Dx kit. A custom NGS-based panel sequences six SNPs on the Illumina MiSeqDx, with no-template and positive controls in every run.

3

Bioinformatics pipeline

A full pipeline calls the variants, assigns HLA-DQ haplotypes and reports one of 15 genotypes with a risk category.

4

Protocols and validation

We wrote the study protocols and ran every analytical study: accuracy, precision, DNA extraction, detection limit and interference.

5

Data analysis and submission

We analyzed all of the validation data, including a user comprehension study showing adults could read their report without a clinician.

6

Site-specific clearance

Validation ran on the instruments, reagent lots and operators at PacificDx, the CLIA-certified laboratory that now performs the cleared test.

Validation results

No incorrect genotype calls in any analytical study

Accuracy and precision studies returned 100% correct calls. In the interference studies, the few samples with low DNA or coverage were flagged for rerun rather than miscalled.

Accuracy vs Sanger sequencing

100% agreement

203 results across four haplotypes (95% CI 98.1–100%)

Precision

270/270 correct

30 samples, 3 reagent lots, 3 sequencers, 3 operators, 3 days (95% CI 98.6–100%)

DNA extraction and lot-to-lot

198/198 correct

144 extraction results from 12 donors; 54 results across 3 lots

Limit of detection

1 ng/µL

108 results at 10, 5 and 1 ng/µL across 3 lots, all correct

Interference

0 incorrect calls

Saliva components, oral microbes, food, drink, gum, mouthwash and smoking; 405 results

User comprehension

97.0%

343 eligible adults understood their report after reading it (target 90%)

The interference studies set the collection instruction: collect saliva at least 30 minutes after eating, drinking, smoking or brushing teeth.

The outcome

Cleared, and running at PacificDx

The project went from start to FDA submission in 18 months. FDA cleared GlutenID as a Class II device (K241456), announced on January 28, 2025. Consumers order the test, collect saliva at home and mail it to PacificDx, the one laboratory covered by the clearance, which runs the assay and returns a risk report.

“This outcome is the result of our team's hard work to bring about this important FDA clearance.”

Shelly Gunn, Medical Director, Targeted Genomics

“We are thrilled to have worked with Targeted Genomics to receive FDA 510(k) approval for this innovative diagnostic platform.”

Mathew Moore, Principal, ResearchDx

Sources: FDA 510(k) decision summary, K241456 (PDF) · Press release, January 28, 2025 (PDF)

Planning a 510(k), De Novo or PMA submission?

From assay design and validation to a site-specific clearance in our CLIA/CAP laboratory, talk to our regulatory team about your device's pathway.